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Current mass drug administration (MDA) programs for the treatment of human river blind-
ness (onchocerciasis) caused by the filarial worm Onchocerca volvulus rely on ivermectin,
an anthelmintic originally developed for animal health. These treatments are primarily
directed against migrating microfilariae and also suppress fecundity for several months,
but fail to eliminate adult O. volvulus. Therefore, elimination programs need time frames
of decades, well exceeding the life span of adult worms. The situation is worsened by
decreased ivermectin efficacy after long-term therapy. To improve treatment options against
onchocerciasis, a drug development candidate should ideally kill or irreversibly sterilize
adult worms. Emodepside is a broad-spectrum anthelmintic used for the treatment of para-
sitic nematodes in cats and dogs (Profender and Procox). Our current knowledge of the
pharmacology of emodepside is the result of more than 2 decades of intensive collaborative
research between academia and the pharmaceutical industry. Emodepside has a novel
mode of action with a broad spectrum of activity, including against extraintestinal nematode
stages such as migrating larvae or macrofilariae. Therefore, emodepside is considered to
be among the most promising candidates for evaluation as an adulticide treatment against
onchocerciasis. Consequently, in 2014, Bayer and the Drugs for Neglected Diseases initia-
tive (DNDi) started a collaboration to develop emodepside for the treatment of patients suf-
fering from the disease. Macrofilaricidal activity has been demonstrated in various models,
including Onchocerca ochengi in cattle, the parasite most closely related to O. volvulus.
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Emodepside has now successfully passed Phase I clinical trials, and a Phase II study is
planned. This Bayer–DNDi partnership is an outstanding example of “One World Health,”
in which experience gained in veterinary science and drug development is translated to
human health and leads to improved tools to combat neglected tropical diseases (NTDs)
and shorten development pathways and timelines in an otherwise neglected area.
Author summary
Onchocerca volvulus is the causative agent of human river blindness, and current elimina-
tion programs rely on the use of ivermectin to kill microfilariae. Since no adulticidal drug
is available and adult worms have a life span of up to 15 years, elimination programs need
to be sustained over several decades. Emodepside is an anthelmintic that is licensed as a
dewormer for cats and dogs. Due to its ability to eliminate nematodes located in various
extraintestinal host tissues, including migrating larvae and adult filarial worms, it is con-
sidered to be an excellent candidate for the treatment of onchocerciasis. Intense collabora-
tion between academia and the pharmaceutical industry has led to a deep understanding
of the novel mode of action of the drug and of its parasite target spectrum. Phase I clinical
trials with emodepside have demonstrated its safety and adulticide activity against the
closely related cattle parasite Onchocerca ochengi. Currently, Phase II clinical trials are
planned to confirm that emodepside, developed initially to improve animal health, has
also the potential to improve human health by tackling a very important neglected tropical
disease (NTD).
Elimination of onchocerciasis—Current status and the need for
novel treatment strategies
Onchocerciasis, also known as river blindness, is a parasitic, vector-borne disease caused by
the filarial nematode Onchocerca volvulus. Filarial diseases such as onchocerciasis and lym-
phatic filariasis place a tremendous burden on society, with more than 1 billion of the world’s
poorest populations at risk of infection [1,2]. Despite O. volvulus being one of the most preva-
lent species (see S1 Fig for global distribution), with 21 million people infected and approxi-
mately 90 million people at risk of infection in sub-Saharan Africa, plus 14.6 million people
suffering from skin disease and approximately 0.77 million people debilitated by severe vision
impairment or blindness, its elimination is considered to be possible [3–6].
Four life stages of O. volvulus live in humans. Infective third-stage larvae (L3) transmitted
by the vector (i.e., a species of the genus Simulium [black flies]) undergo 2 molts to develop via
fourth-stage larvae (L4) into juvenile adults. These mature to become reproductively compe-
tent adults (male and female macrofilariae) within around 1 year and have an estimated mean
reproductive life span of up to 15 years [7]. Macrofilariae reside primarily in subcutaneous and
deep tissue nodules and produce progeny (microfilariae) that live for approximately 1 year,
predominantly in the subepidermal layer of the dermis. During the blood meal, female Simu-
lium take up microfilariae, which then develop via second-stage larvae (L2) into infective L3 in
the insect’s thoracic muscles to complete the life cycle of the parasite [8] (see S2 Fig for illustra-
tion of the life cycle).
Onchocerciasis causes severe itching, disfiguring skin lesions, and depigmentation, along
with musculoskeletal pain, reduced body mass index, and decreased work productivity [9,10].
The most severe complications attributed to onchocerciasis are severe visual impairment in up
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to 500,000 cases, blindness in about 270,000 cases, and reduced life expectancy [6,11], although
these figures are considered to underestimate the true magnitude of the socioeconomic burden
of onchocerciasis [9]. The disease is the second most frequent cause of infectious blindness
after trachoma, with almost all cases seen in sub-Saharan Africa [3].
Mass drug administration (MDA) is a means of delivering safe and inexpensive essential
medicines based on the principles of preventive chemotherapy, in which populations or sub-
populations are offered treatment without individual diagnoses. MDA in endemic areas aims
to prevent and alleviate symptoms and morbidity on the one hand and reduce transmission on
the other, together improving global health. At present, MDA with ivermectin (Mectizan,
Merck, Kenilworth, New Jersey, USA) is the current measure to achieve elimination of oncho-
cerciasis [12–14]. Since ivermectin does not kill the adult worms, it has to be given once or
twice per year and is contraindicated in individuals harboring high numbers of Loa loa micro-
filariae due to the risk of life-threatening adverse events [15–17].
Insufficient coverage is one of the main factors hindering progress toward elimination. Rea-
sons for this are many, including difficult to treat areas (L. loa coinfection, ongoing conflicts),
lack of financial resources, and inadequate political engagement. Additionally, program fatigue
in MDA has been reported after years of implementation, and an individual in an endemic
area may find repeated MDA inconvenient or lose confidence in the MDA campaign. Further-
more, alarming reports of reduced drug efficacy in Ghana and Cameroon may also signal the
development of resistance [18,19]. This situation, coupled with the risk of ivermectin resis-
tance, presents an urgent need for a novel anthelmintic drug that preferably possesses macrofi-
laricidal or permanent sterilizing activity.
Drug development is handicapped by high attrition rates, and many promising molecules
fail during preclinical development or in subsequent toxicological, safety, and efficacy testing;
thus, research and development (R&D) costs in aggregate are very high. The level of invest-
ment into R&D for new products for neglected tropical diseases (NTDs), as reported in the
annual Global Funding of Innovation for Neglected Diseases (G-FINDER) surveys, suggests
that few NTD areas receive anywhere near the level of funding required; moreover, that fund-
ing, when it is available, is rarely allocated in a manner likely to move products through the
pipeline to patients [20]. Therefore, no dedicated drug development pipeline for human filaria-
sis is in place, and it is thus essential that stakeholders, funders, industry, academics, and non-
governmental organizations adopt a cooperative approach, sharing responsibility to reduce
risks and overcome existing obstacles. Joint efforts should also be made to cut the cost of R&D
for new drugs for NTDs.
The semisynthetic anthelminthic emodepside (synonyms: PF1022-221, BAY 44–4400, or
bismorpholino–cyclooctadepsipeptide) and its parent fermentation product PF1022A are
members of the N-methylated cyclooctadepsipeptides (Fig 1). Emodepside is characterized by
2 morpholine rings in para-position of each of the 2 (R)-phenyllactic acids (Fig 1A), which
increase solubility and improve bioavailability in comparison to its natural precursor PF1022A
(Fig 1B) [21]. This precursor is obtained from a fungus (Rosellinia sp. PF1022), which is part
of the microflora of the leaves of Camellia japonica [22]. Emodepside is registered as a combi-
nation product with praziquantel (Profender) for the treatment of cats and dogs infected with,
or at risk of, infection with nematodes and cestodes and as a combination product with toltra-
zuril (Procox) for the treatment of puppies with demonstrated or suspected infection with
nematodes and coccidia.
Emodepside has been shown to be microfilaricidal, as well as macrofilaricidal, and has a
unique mechanism of action relative to all other anthelmintic drugs [22,23]. The advantage of
emodepside over ivermectin is that it targets multiple life cycle stages of filariae, including the
adult worms [24]. In the case of the genus Onchocerca, the in vitro motility of macrofilariae is
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affected at lower concentrations than that of the microfilariae [24]. Targeting macrofilariae is
expected to result in a reduction in the number of MDA treatment cycles required to break
transmission and cure patients of both migrating microfilariae as well as macrofilariae.
Since standard treatment with ivermectin is contraindicated in patients coinfected with L.
loa, availability of an anthelmintic that can be used in regions where loiasis and onchocerciasis
are co-endemic would add considerable value toward the goal of eliminating onchocerciasis
[15–17]. As to date, emodepside has not been given to patients infected with O. volvulus, there
is obviously no data on patients being coinfected with L. loa. Thus, after determining the emo-
depside efficacy and safety profile in patients infected with O. volvulus, a next step might be to
test it in patients coinfected with L. loa (low microfilariae level) to evaluate the potential benefit
in those patients.
The in vivo anthelmintic efficacy of the fermentation product PF1022A was originally dem-
onstrated against the gastrointestinal nematode Ascaridia galli in chickens in 1992 [25], fol-
lowed by reports of anthelminthic effects against a wide range of gastrointestinal nematodes in
rats [26–28], mice [29–31], jirds [32], dogs, horses, sheep, and cattle [27]. In addition, emodep-
side showed efficacy against further species of parasitic nematodes in a variety of hosts, includ-
ing cerebral and other extraintestinal life cycle stages [22,33–41]. Emodepside has an excellent
safety profile, with neurotoxicological side effects only reported rarely in dogs with the multi-
drug resistance 1 (mdr-1) mutation [42]. More importantly, it has been shown to have anthel-
mintic resistance–breaking properties against several nematode isolates resistant to closantel,
fenbantel, fenbendazole, levamisole, and ivermectin in sheep and cattle and against a multi-
drug-resistant Ancylostoma caninum isolate in dogs [43,44].
In addition to its well-known use as an anthelmintic in cats and dogs, the microfilaricidal
and macrofilaricidal effects of emodepside have led to the compound being considered as a
promising drug development candidate for the treatment of human helminth diseases, includ-
ing onchocerciasis [22,45,46]. As a result, emodepside is currently being evaluated for the
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treatment of human onchocerciasis within the scope of a drug development partnership
between the Drugs for Neglected Diseases initiative (DNDi) and Bayer [47]. Phase I clinical tri-
als have already been completed successfully [48], and a Phase II trial is planned in 2021.
Here, we outline the development of emodepside for human onchocerciasis, review the elu-
cidation of its novel mode of action and its efficacy against filarial nematodes, both in vitro
and in vivo, and describe the initial studies with this encouraging agent in humans.
Emodepside—Novel mode of action and broad-spectrum activity
History of the cyclooctadepsipeptide anthelmintics
A flow diagram presenting the most important steps leading from the isolation of PF1022A to
human trials evaluating safety and efficacy of the drug is available in Fig 2. In 1992, researchers
from Meiji Seika Kaisha (Tokyo, Japan) isolated a new family of N-methylated cyclooctadepsi-
peptides [49]. The fungus Rosellinia spp. PF1022 produces 8 different cyclooctadepsipeptides,
designated PF1022A, B, C, D, E, F, G, and H, although PF1022A is produced in the highest
amounts by far [50]. PF1022A is also the most potent anthelmintic among the PF1022 mem-
bers; its anthelmintic activities have been summarized in a previous review [22].
Since the efficacy of the parent compound PF1022A is largely limited to intestinal nema-
tode stages in different host species, further research was focused on identifying cyclooctadep-
sipeptides with efficacy against extraintestinal stages (including blood and tissue stages). For
this purpose, a screening program involving Bayer Animal Health (Leverkusen, Germany),
Bayer Crop Science (Monheim, Germany), Meiji Seika Kaisha, and Fujisawa Pharmaceutical
(Japan) was initiated. A patent application was subsequently filed by Fujisawa Pharmaceutical
for a bis-morpholino derivative of PF1022A, which was later named emodepside [22].
Elucidation of the mode of action
Ionotropic γ-aminobutyric acid receptors
Initial studies investigating the mechanism of action of PF1022A found high binding affinity
of the cyclooctadepsipeptide to Ascaris suum cell membranes, suggesting that there are specific
PF1022A binding sites in the membrane preparations that are responsible for its nematocidal
activity [51]. PF1022A was also shown to displace radioactive γ-aminobutyric acid (GABA)
from A. suum muscle cells, suggesting an interaction of PF1022A with ionotropic GABAA
receptors [52]. However, PF1022A does not appear to act like a GABA agonist in A. suum
muscle cells since it does not produce an increase in muscle membrane conductance similar to
GABA [53,54]. Nevertheless, a loss-of-function mutation of the only GABAA receptor gene
unc-49 in the Caenorhabditis elegans genome has been shown to cause decreased susceptibility
to emodepside [55].
Latrophilin receptors
The first target of cyclooctadepsipeptides identified in nematodes was the Haemonchus contor-
tus latrophilin-like receptor (LAT-1) [56]. An affinity screen of an H. contortus cDNA expres-
sion library identified a G protein–coupled receptor (GPCR) that bound PF1022A [56].
Expression of the full-length H. contortus LAT-1 in HEK293 cells further supported its poten-
tial to act as a receptor for latrotoxin since it initiated downstream Ca2+ influx through Cd2+
and nifedipine blockable channels (L-type Ca2+ channels). Moreover, emodepside, but not its
anthelmintically inactive enantiomer, decreased the response of the H. contortus LAT-1 recep-
tor to latrotoxin [56].
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In C. elegans, simultaneous deletion of both latrophilin paralogs, lat-1 and lat-2, decreased
the susceptibility of the pharynx to emodepside [57]. In contrast to lat-1, deletion of compo-
nents of the signaling cascade downstream of the LAT-1 receptor, such as egl-30 and egl-8,
causes a decrease in emodepside susceptibility of both pharynx and body wall muscles, yet an
egl-30 gain-of-function mutant increases susceptibility [58]. The impact of defects downstream
of LAT-1 on emodepside activity on the pharynx were always more severe than effects of LAT-
1 [58]. This suggests that emodepside can directly exert its effects through LAT-1 on the phar-
ynx, with upstream GPCRs augmenting emodepside’s effects on body wall muscles.
Fig 2. Flow chart summarizing the most important achievements from the isolation of PF1022A to recent and future human trials. Milestones with
pharmaceutical industry in lead are shown in blue, and milestones achieved with academia in lead are shown in yellow. BK, Big Potassium; DNDi, Drugs for Neglected
Diseases initiative; LAT-1, latrophilin-like receptor.
https://doi.org/10.1371/journal.ppat.1009682.g002
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Expression patterns of lat-1 were determined in C. elegans using a fluorescent reporter gene
construct [44,45,47]. In larvae, the promotor was active in neuronal and muscle cells around
the pharynx. In contrast, promotor activity ceased in adult worms (which show the highest
susceptibility to emodepside) and was limited to neuronal cells [23,59,60]. In contrast, Buxton
and colleagues [61] showed expression of lat-1 mRNA in muscle flaps of A. suum containing
both muscle cells and axons of neuronal cells present in the dorsal and ventral cords. It cur-
rently remains unclear if these contrasting results are due to differences between nematode
species or the different sensitivities of the methods used. It is also uncertain if emodepside is
able to directly modulate LAT-1 from ascarids, since sequence identity between A. suum and
C. elegans proteins is only 38% (54% similarity) [61].
In terms of understanding the mode of action of emodepside, it is important to note that
C. elegans with double deletion of lat-1 and lat-2 are still nonviable in emodepside [58], sug-
gesting that while latrophilin is a target of emodepside, other targets must also be key to its
anthelmintic action. Knowledge regarding the different pathways involved in the effects of
emodepside in nematode neurons and muscle cells is graphically summarized in Fig 3.
Voltage-gated and Ca2+-activated potassium channels (SLO-1)
In order to determine the molecular mediators of the latrophilin-independent effect of emo-
depside, a genetic screen in C. elegans revealed resistant worms with mutations in alleles of slo-
1 encoding a calcium-activated potassium channel [23,66]. SLO-1 channels are important for
rapid repolarization of cells after depolarization during action potentials; a functional channel
is made up of 4 subunits containing 7 transmembrane helices each (Fig 4). A functional null
mutant of slo-1 was found to develop and feed normally in the presence of a concentration of
emodepside that impairs development, inhibits feeding, and paralyzes wild-type worms [67].
Interestingly C. elegans strains carrying slo-1 gain-of-function mutations are sluggish, immo-
tile, and retain eggs, phenocopying the effect of emodepside on C. elegans behavior [68]. These
observations suggest that emodepside is a SLO-1 agonist, activating potassium currents to
inhibit neuromuscular function. This has been confirmed through heterologous expression of
slo-1 in C. elegans pharyngeal muscle [63], HEK293 cells [60], and Xenopus oocytes [59,60].
The role of SLO-1 in the toxicity of emodepside to parasitic nematodes of companion ani-
mals and livestock was confirmed by the cloning of slo-1 from A. caninum and Cooperia onco-
phora and its expression in the C. elegans functional null slo-1 mutant, NM1968 slo-1(js379)V.
Expression of A. caninum and C. oncophora slo-1 genes in NM1968 was found to confer emo-
depside sensitivity to this otherwise unresponsive mutant and ameliorate the locomotor deficit
of the C. elegans slo-1 null background [62]. This provides strong evidence that emodepside
exerts its anthelmintic action in both nematode species (A. caninum and C. oncophora)
through the activation of SLO-1. The conservation of slo-1 in the phylum Nematoda provides
further evidence that this is the major determinant of its selective anthelmintic action (see
Fig 5) [59].
To address the selective toxicity of emodepside in terms of its impact on the mammalian
host, the actions of the closest human orthologue of C. elegans slo-1, kcnma1, was investigated.
While emodepside was found to be a potent and prolonged activator of C. elegans SLO-1 heter-
ologously expressed in HEK293 cells, it only caused transient activation of KCNMA1, followed
by inhibition [60]. In the same study, emodepside also activated Drosophila slo-1, although its
ability to modify the rectifying properties of the emodepside-induced current differed from
that seen with C. elegans slo-1 [60]. These functional differences in the interaction of emodep-
side with calcium- and voltage-activated potassium channels provide a mechanistic explana-
tion for its selective anthelmintic action.
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A recent study used comparison of C. elegans wild strains with the N2 Bristol laboratory
strain regarding emodepside responsiveness [72]. The authors found that there was substantial
natural variation in susceptibility to emodepside. Some but not all of this variation could be
explained by variation in the SLO-1 channel. The remaining variation was not explainable by
variation in LAT-1, suggesting that there are additional genetic factors contributing to the
level of emodepside susceptibility. These might include any of the signal transduction pathway
components downstream of LAT-1 identified previously [58] and depicted in Fig 3 or addi-
tional, currently unidentified loci.
Taken together, the studies in C. elegans and parasitic nematodes have identified the cal-
cium- and voltage-activated potassium channel SLO-1 as the major receptor mediating
emodepside’s anthelmintic action. The identity and properties of the pharmacophore for emo-
depside harbored by the channel remain a topic of speculation, although its physicochemical
properties and profile of effects suggest a binding site within the membrane at a lipid:protein
Fig 3. Graphical summary describing the signaling pathways potentially involved in Emo effects in nematodes. Signaling pathways are shown separately for pharynx
(A) and body wall muscles (B). In several cases, there is no clear or unequivocal evidence for the presence/activity of the signaling component in the particular
compartment. In these cases, question marks and dotted lines indicate these uncertainties. Emo directly interacts with the ionotropic GABAA-R UNC-49 [52], with LAT-
1 [56] and with the voltage-gated Ca2+-activated potassium channel slowpoke big K+ conductance channel (SLO-1) [59,60]. However, Caenorhabditis elegans lines with
loss-of-function mutations in unc-49, lat-1, or both lat-1 and lat-2 genes display only modest decreases in their Emo sensitivity [55,57,58]. In contrast, loss of SLO-1
function in C. elegans leads to complete loss of Emo efficacy, which can be restored by expression of SLO-1 from parasitic nematodes, but only partially by the human
orthologue [23,62,63]. This shows that activation of SLO-1 [59,60] is the major effect leading to Emo-induced paralysis as indicated by bold arrows. Activation of SLO-1
or GABAA-R UNC-49 can lead directly to membrane hyperpolarization, and, thus, to reduced excitation. UNC-49 is only expressed on body wall muscles (postsynaptic
side) [64]. In contrast, SLO-1 channels can be found on presynaptic nerves innervating both pharynx and body wall muscles, as well as on body wall muscles themselves,
being absent from pharyngeal muscles [63]. LAT-1 (and potentially other, unidentified GPCRs [orphan receptors]) is assumed to exert its effects via a signal transduction
cascade involving an hGp containing the EGL-30 Gqa subunit, leading to activation of the PLC EGL-8 [56–58]. PLC activity hydrolyses PIP2 to DAG and IP3. The latter
leads to release of Ca2+ from intracellular stores. DAG and Ca2+ are both required to activate PKC-β, which is known to be able to modulate SLO-1 responsiveness [61].
On the presynaptic side, DAG is further known to facilitate release of vesicles via the synaptobrevin SNB-1 and UNC-13, a protein essential for presynaptic vesicle release
[57]. In C. elegans, these signaling pathways are also active in presynaptic neurons and postsynaptic body wall muscle cells [58]. In parasitic nematodes, the situation may
be different since lat-1 mRNA was detected in Ascaris suum body wall flaps, suggesting that the receptor is expressed in motor neurons and/or body wall muscles [61].
Moreover, NO has been shown to increase potassium currents induced by Emo in A. suum muscle preparations [61]. It is currently unclear how NO exerts its effect since
nematode soluble guanylate cyclases, in contrast to the mammalian enzymes, are not activated by NO [65]. DAG, diacyl glycerol; Emo, Emodepside; GABAA-R, γ-
aminobutyric acid A receptor; GPCR, G protein–coupled receptor; hGp, heterotrimeric G protein; IP3, inositol 1,4,5-trisphosphate; LAT-1, latrophilin-1; NO, nitric
oxide; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC-β, protein kinase C β; PLC, phospholipase C; SLO-1, slowpoke big K+ conductance channel.
https://doi.org/10.1371/journal.ppat.1009682.g003
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interface [58]. However, elucidating the interaction of emodepside with SLO-1 was an impor-
tant step toward understanding the molecular basis of its mode of action.
Emodepside as a filaricidal agent
There is an urgent need for an orally delivered macrofilaricidal drug suitable for MDA pro-
grams. In light of the success of emodepside as a veterinary anthelmintic [22], studies to evalu-
ate the efficacy of this drug against filarial nematodes were planned. Initial studies employed
in vivo filarial models in the southern multimammate mouse, Mastomys coucha [73]. Here, it
was shown that a single dose of emodepside (100 mg/kg) applied as a spot-on formulation was
able to substantially suppress microfilaremia in Acanthocheilonema viteae and Litomosoides
sigmodontis infections for at least 100 days and in Brugia malayi infections for at least 150
days, when the drug was administered during the maturation of adult worms [73]. Only larval
and preadult stages of A. viteae, and not those of L. sigmodontis and B. malayi, were affected by
this treatment. A single dose of oral, subcutaneous, or spot-on treatment of 100 mg/kg emo-
depside has also been shown to eliminate all adult A. viteae in the same model [74]. In contrast,
elimination of adult L. sigmodontis required repeated oral treatment of 100 mg/kg emodepside
on 5 consecutive days, whereas adult B. malayi were not eliminated by this treatment schedule
[74]. Nevertheless, severe pathological alterations in the intrauterine stages of all 3 parasite spe-
cies were noted at a much lower single dose of emodepside, which is likely to explain the long-
term effects of the drug on microfilarial density [73,74]. A direct microfilaricidal effect of emo-
depside was further shown in mice injected with microfilariae of Onchocerca lienalis at doses
of�5 × 1.56 mg/kg [75].
The abovementioned in vivo studies showed that emodepside clears microfilariae of differ-
ent filarial species, but has a less pronounced effect on the adult filarial burden. However, in
vitro studies using a 4-day assay analyzing the motility of L. sigmodontis adult male and female
worms showed complete inhibition of motility in both sexes at emodepside concentrations as
low as 1 × 10−8 M. L. sigmodontis microfilariae and L3 larvae were less susceptible to emodep-
side, with complete motility inhibition demonstrated in a 4- and 3-day in vitro assay at an IC50
of 5 × 10−9 M and 3.5 × 10−7, respectively. Similarly, for microfilariae of A. viteae and B.
Fig 4. Schematic drawings showing domain composition (A) and topology in the plasma membrane of a SLO-1
subunit (B). The scheme in (A) is drawn to scale based on Onchocerca volvulus SLO-1a (GenBank accession number:
MW039265; the protein contains 7 transmembrane domains. The transmembrane domains S2–S4 contain charged
amino acids and function as voltage sensor, while S5 and S6 are involved in building the pore. For this purpose, 4
subunits form a tetramer. The P loop is involved in tetramer formation and pore building. The 2 RCK domains and
the Ca2+ bowl are involved in regulation of conductance by intracellular Ca2+ levels. P loop, pore-forming loop; PM,
plasma membrane; RCK, regulator of potassium conductance; SLO-1, slowpoke big K+ conductance channel.
https://doi.org/10.1371/journal.ppat.1009682.g004
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Fig 5. Phylogenetic analysis of nematode SLO-1 channels. (A) Maximum likelihood phylogram calculated from full-length Slo-1 proteins. Slo-1 sequences from the
nematode species Cel, Cbr, Cre, Pca, Hco, Con, Acan, Ovo, Ooc, Ogu, Bma, Dim, Tca, Peq, Asu, Tmu, and Tsu were aligned with orthologs from Dme, Aga, Phu, Dpu, Acal,
Gal, Bta, and Hsa, representing an outgroup, using MCoffee [69]. For Onchocerca spp. and Brugia malayi, all splice variants were included, but only the variants slo-1a-c
for Caenorhabditis elegans. For all other species, only a single splice variant was used per gene. Accession numbers are available in S1 Table. ModelFinder [70] was
applied to identify the optimal amino acid substitution model. The VT+G4 amino acid substitution model was used with a Γ shape alpha set to 0.4242 and the 4
substitution relative rate categories (with equal frequencies) of 0.0203, 0.1996, 0.7562, and 3.0239. Maximum likelihood trees were calculated with IQ-TREE [71] using
2,000 iterations of the Shimodaira–Hasegawa modification of the approximate likelihood ratio test (before the slash) and 2,000 ultrafast bootstrapping replicates (behind
the slash). The scale bar represents 0.3 substitutions per site. (B) Enlarged cladogram showing the relationship of filarial SLO-1 proteins. For clarity, node support values
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malayi, complete inhibition of motility in a 4- and 3-day in vitro assay was demonstrated at an
IC50 of 1.5 × 10−8 M and 6.4 × 10−8 M, respectively [24].
Further studies used several in vitro and in vivo systems that have been developed to study
drug effects on Onchocerca spp. and Brugia spp. (see [5]). Utilizing these protocols, the efficacy
of emodepside against 3 species of filarial parasites was evaluated, examining the effects of
drug concentration and duration of exposure on adult male Onchocerca gutturosa, adult male
and female Brugia pahangi, and microfilariae of O. lienalis in vitro [75]. The effects of drug
dosage, formulation and route of administration on the survival of O. lienalis microfilariae in
mice were also assessed [75].
O. gutturosa adult males obtained from the nuchal ligament connective tissues of naturally
infected cattle were tested in a 5-day in vitro assay (concentration range 2.95 × 10−12 M to
1.25 × 10−5 M). Emodepside immobilized them at a concentration of�4.8 × 10−8 M, produc-
ing an EC50 for motility of 9 × 10−10 M [35]. However, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT)/formazan colorimetry results demonstrated that emodepside
concentrations�1.25 × 10−5 M had no significant effect on macrofilarial viability, indicating
that the worms were paralyzed, but not dead, after 5 days exposure to emodepside. A subse-
quent long-term in vitro assay confirmed that 5-day exposure to 1.25 × 10−5 M emodepside
killed (measured both by motility and MTT colorimetry) O. gutturosa adult males after a total
of 40 days of culture, indicating that worms did not recover following the initial 5-day expo-
sure to emodepside [75].
Macrofilaricidal properties of emodepside were also evaluated against adult male and
female B. pahangi in vitro [75]. These parasites were significantly less sensitive to emodepside
than O. gutturosa, with B. pahangi parasites remaining active at a low level at 1.25 × 10−5 M in
a 5-day assay, resulting in a sex-dependent motility EC50 of 6 × 10−8 M for male worms and
4.3 × 10−7 M for females. Poor motility was also observed throughout a 10-day trial in which
worms were transferred to a drug-free medium on day 5, with a similar partial effect seen on
MTT values, indicating a significant drug effect, but not death [75].
Sex-dependent effects of emodepside have also recently been reported for B. malayi [76]. In
particular, male and female worms have been shown to express distinctive splice variants of
the emodepside target SLO-1, which differ greatly in their responsiveness to emodepside, pre-
sumably accounting for the major differences in emodepside susceptibility between the differ-
ent sexes in this species.
A summary of studies investigating the activity of emodepside against filaria is provided in
Table 1.
Development of emodepside for onchocerciasis
From animal health to neglected tropical diseases
Knowledge of the safety, efficacy, and pharmacokinetics (PK) of pharmaceuticals in animals
can allow for a rapid transition into human use. Thus, veterinary anthelmintics should be con-
sidered as a priority for use against helminth parasites in humans, where there are still unmet
needs [46,77].
for this part of the tree are only indicated in B. Acal, Aplysia californica; Acan, Ancylostoma caninum; Aga, Anopheles gambiae; Asu, Ascaris suum; Bma, Brugia malayi;
Bta, Bos taurus; Cbr, Caenorhabditis briggsae; Cel, Caenorhabditis elegans; Con, Cooperia oncophora; Cre, Caenorhabditis remanei; Dim, Dirofilaria immitis; Dme,
Drosophila melanogaster; Dpu, Daphnia pulex; Gal, Gallus gallus; Hco, Haemonchus contortus; Hsa, Homo sapiens; Ogu, Onchocerca gutturosa; Ooc, Onchocerca ochengi;
Ovo, Onchocerca volvulus; Pca, Pristionchus pacificus; Peq, Parascaris equorum; Phu, Pediculus humanus humanis; SLO-1, slowpoke big K+ conductance channel; Tca,
Toxocara canis; Tmu, Trichuris muris; Tsu, Trichuris suis.
https://doi.org/10.1371/journal.ppat.1009682.g005
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Ivermectin is an example of applying the experience of anthelmintics developed for animal
health to human NTDs. The drug was developed in the mid-1970s for control of livestock
nematodes. By the late 1970s, it was observed that ivermectin was microfilaricidal against
Onchocerca spp. in horses [78] and cattle [79] and prohibited the development of larval stages
of the filarial nematode Dirofilaria immitis in dogs [80]. These observations led to the consid-
eration of ivermectin for the control of O. volvulus [79]. The development of ivermectin for
onchocerciasis, and, more recently for lymphatic filariasis, has been a highlight of efforts to
control NTDs. For both filarial diseases, control programs rely on the microfilaricidal effect
and temporal sterilization of female worms, which inhibit the release of new microfilariae for
several months. For onchocerciasis and lymphatic filariasis control and elimination programs,
ivermectin is donated under the Mectizan Donation Program established by Merck in 1987
[81].
There are a number of other examples of pharmaceuticals that were first developed for use
in animal health ultimately having a huge impact on NTDs. Albendazole and mebendazole
were first developed for animal health and have subsequently been used to control human soil-
transmitted helminths (STHs) [82]. Hundreds of millions of doses per year of these anthelmin-
tics are now donated for control of STH and lymphatic filariasis (albendazole) in humans.
Another example, praziquantel, developed by Bayer and E. Merck (Merck Group), was pat-
ented initially as a veterinary drug. Subsequently, it was shown to be highly efficacious against
human schistosomes, and it became essential in the fight against NTDs [83].
Bayer has a long history of discovering drugs for the treatment of NTDs. It developed a
number of antiprotozoal drugs that are of considerable importance, including the suramin
(Naganol) against African trypanosomiasis (discovered in 1924), the antimalarial drug chloro-
quine (in 1934 to 1937), and nifurtimox against Chagas disease (in 1972) [84]. Bayer-devel-
oped anthelmintics include antimosan against Schistosoma mansoni (in 1931), Miracil D
(lucanthone) against some schistosomes (in 1940), and niclosamide (in 1953), which was used
against tapeworms before the discovery of praziquantel [85]. Now, emodepside is the latest
Bayer drug entering the field of tropical medicine.
Table 1. Efficacy studies for emodepside against filaria.
Filaria species Emodepside efficacy Reference
In vitro studies
Litomosoides sigmodontis Adult worms: complete motility inhibition (IC50 1 × 10−8 M)a
L3: complete motility inhibition (IC50 9 × 10−9 M)a
[24]
Acanthocheilonema viteae MF: complete motility inhibition (IC50 1 × 10−9 M)a [24]
Brugia malayi MF: complete motility inhibition (IC50 1 × 10−9 M)a [24]
Onchocerca gutturosa Adult male worms: complete motility inhibition (EC50 9 × 10−10 M)b [75]
Brugia pahangi Adult male worms: reduced motility (EC50 6 × 10−8 M)b [75]
Adult female worms: reduced motility (EC50 4.3 × 10−7 M)b
In vivo studies in mice
A. viteae MF: elimination for�100 days (100 mg/kg emodepside) [73]
Adult worms: elimination within 56 days (100 mg/kg emodepside) [74]
L. sigmodontis MF: elimination for�150 days (100 mg/kg emodepside) [73]
Adult worms: elimination within 56 days (5 × 100 mg/kg emodepside) [74]
B. malayi Intrauterine stages: severe pathological alterations (25 mg/kg emodepside) [74]
a4-day assay.
b4-day assay.
L3, third-stage larvae; MF, microfilariae.
https://doi.org/10.1371/journal.ppat.1009682.t001
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The DNDi, a collaborative, patient needs–driven, not-for-profit R&D organization, was
founded in 2003. DNDi’s primary focus is the development of drugs for the treatment of the
most neglected diseases around the world [86]. In 2010, DNDi approved the inclusion of filar-
ial diseases in its portfolio aiming to develop a safe, efficacious, affordable, and field-adapted
drug targeting macrofilariae against onchocerciasis and/or lymphatic filariasis. One of the
strategies pursued was to identify veterinary drugs and evaluate their suitability for develop-
ment as macrofilaricides for human use [47].
Emodepside was originally identified as a potential macrofilaricide through a drug discov-
ery effort aiming to identify macrofilaricidal drugs for filarial diseases sponsored by WHO
Special Programme for Research and Training in Tropical Diseases (WHO-TDR) in the early
2000s [3,75,87]. In 2014, DNDi and Bayer signed an agreement for a collaboration on the
development of emodepside as a potential treatment for onchocerciasis [47]. The scope of this
agreement was to conduct a gap analysis of the veterinarian safety package as part of the com-
pletion of an investigational medicinal product dossier (IMPD). In addition, in vitro and in
vivo studies were conducted with L. sigmodontis [24,88], a surrogate filarial nematode for effi-
cacy against O. volvulus [89–91]. In the agreement, Bayer committed to conduct pharmaceuti-
cal development and supply of the drug, while DNDi was responsible for both nonclinical and
clinical development of the molecule.
The Onchocerca ochengi/cattle model for preclinical proof of concept
O. ochengi is a sibling species to O. volvulus [92,93] infecting cattle, which is widely used for
research into the basic biology of Onchocerca spp., drug effects, and vaccine candidates [94].
To assess the predictability of emodepside effects in the O. ochengi cattle model for human
onchocerciasis, a recent study compared the emodepside susceptibility of SLO-1 of both
Onchocerca species. A comparison of amino acid sequences from different isolated isoforms
indicated that SLO-1 is highly conserved between both species (Fig 5). Moreover, when func-
tionally expressed in the Xenopus oocyte expression system, O. ochengi and O. volvulus SLO-1
isoforms were all able to form homomeric channels, showing comparable levels of emodepside
sensitivity [95].
In order to obtain reliable data using the O. ochengi/cattle model, it is crucial to achieve
drug concentrations at the target site that are comparable with those in humans. The maxi-
mum tolerated dose (MTD) of emodepside in taurine Holstein cattle was found to be 1 mg/
kg, but 0.75 mg/kg was used conservatively in indicine (zebu) cattle in Cameroon to com-
pensate for environmental stresses [96]. Analytical methods were also established to deter-
mine emodepside concentrations in skin and nodules containing adult O. ochengi after
administration of different doses showing that an intravenous dose of 0.15 mg/kg in cattle
was equivalent to 10 mg in humans, achieving the same local target concentration. Using this
model, the density of microfilariae in the skin was not affected by a single 0.15 mg/kg dose of
emodepside. In contrast, a single 0.75 mg/kg dose and 0.15 mg/kg given daily for 7 days tran-
siently reduced microfilarial density [97]. In addition, 0.75 mg/kg emodepside given daily
for 7 days resulted in an initial reduction, then a transient rise followed by complete clear-
ance, of microfilariae in 4 out of 7 animals within 18 months of treatment. The motility of
adult macrofilariae recovered from nodules was significantly affected over time at all emo-
depside doses for females, but only at the highest dose for males [97]. In 5 out of 7 cattle,
including those with no microfilariae, the 7 × 0.75 mg/kg treatment scheme caused death or
sterility of female worms, demonstrating slow-acting macrofilaricidal and sterilizing effects
[98].
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Emodepside in Phase I human trials
Based on the available preclinical data, permission to proceed with Phase I trials was granted
by the United Kingdom Medicines & Healthcare products Regulatory Agency (MHRA), and
the study was initiated in December 2015 in the UK and completed in October 2018. Results
of Phase I studies indicate that predicted efficacious levels could be reached safely in humans
[99].
Phase I clinical trials with emodepside were comprised of single- (NCT02661178) and mul-
tiple-dose (NCT03383614) safety, tolerability, and PK studies and a relative bioavailability
study (NCT03383523). In the single- (0.1 to 40 mg emodepside) and multiple-dose (5 or 10
mg) studies, an oral liquid formulation of emodepside was used, with the multidose escalation
study also comparing emodepside 10 mg daily with 10 mg twice daily. In the bioavailability
study, 2 immediate-release (IR) tablet emodepside formulations were compared with the liq-
uid formulation (5 or 10 mg) [48]. As a liquid service formulation, emodepside was rapidly
absorbed under fasting conditions, with dose-proportional increases in plasma concentrations
at doses from 1 mg to 40 mg. The half-life during the first 24 hours after dosing was around 11
hours, followed by a terminal elimination half-life >500 hours. Emodepside was less bioavail-
able in the fed state. Emodepside was well tolerated overall, with no major safety concerns.
The rate of absorption was slower, and the peak serum concentration (Cmax) was slightly
lower with the amorphous solid dispersion tablets than with the liquid service formulation
(NCT03383614, NCT02661178, and NCT03383523). These data enabled us to select a
field-adapted tablet formulation that will open the way for further clinical development of
emodepside in individuals with onchocerciasis. In terms of macrofilaricidal activity, a target
concentration corresponding to the in vitro minimum inhibitory concentration against L. sig-
modontis of 100 ng/ml was assumed to be required. Simulation studies were used to model
dosing regimens that would achieve such a target site concentration. A 15-mg dose with the
gastrosoluble tablet is predicted to provide exposure that will achieve the target concentration
for clinical efficacy [48,99].
A Phase II clinical trial will take place in Hohoe, Ghana. The study is a randomized, dou-
ble-blind, parallel group trial to investigate emodepside in subjects with O. volvulus infection,
comprising 2 parts. In part 1, the safety, tolerability, pharmacodynamics, PK, and dose–
response relationship for efficacy (proof of concept) was investigated. In part 2, the efficacy of
selected doses, safety, tolerability, and PK will be investigated [100].
Beyond onchocerciasis—Should emodepside be considered for
human soil-transmitted helminths?
STH infections, including Ascaris lumbricoides, Trichuris trichiura, and the 2 hookworm spe-
cies Ancylostoma duodenale and Necator americanus, are highly prevalent and responsible for
a considerable public health burden [101]. Chemotherapy is the strategy of choice for treat-
ment and control of these infections. However, there is a need to discover and develop alterna-
tive drugs since treatment options are limited, drug resistance is a concern, and, importantly,
the 2 most widely used drugs, the benzimidazoles albendazole and mebendazole, have limited
activity against T. trichiura when used in a single-dose regimen [102]. Given the limited drug
discovery pipeline for STH infections, veterinary anthelmintics are an attractive starting point
for crossover development for the treatment of these diseases, particularly given the fact that
almost all drugs against these pathogens have been introduced initially into the veterinary mar-
ket (see above).
Emodepside could be an excellent drug candidate for the treatment of STH infections. In
S2 Table, studies conducted to date investigating the activity of emodepside against Trichuris
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spp., ascarids, Strongyloides ratti, and hookworm species have been summarized. Briefly, emo-
depside is highly active against T. vulpis in dogs at single oral doses of 0.5 to 2 mg/kg [37]. In
the T. muris mouse model, an ED95 of 24.5 mg/kg for oral treatment was calculated [103],
while a recent study reported an ED50 of 1.2 mg/kg and complete clearance of the parasites at
75 mg/kg for a single oral treatment [104]; for comparison, an ED50 of 4.7 mg/kg was recently
determined for a single dose of oxantel pamoate against T. muris in mice [105]. A single dose
of emodepside was shown to be highly effective against ascarids in cats (Toxocara cati and Tox-
ascaris leonina) and dogs (Toxocara canis and T. leonina) [34,38]. Remarkably, it is also able to
suppress galactogenic transmission of T. cati [106]. Studies with emodepside against hook-
worms were conducted with the mouse and rat roundworms Heligmosomoides bakeri and Nip-
postrongylus brasiliensis [107], the zoonotic parasites Ancylostoma tubaeforme [37] and A.
ceylanicum [104] in cats and A. caninum in dogs [39,108], as well as the human parasite N.
americanus in a hamster model [104]. Importantly, emodepside also revealed activity against
Strongyloides, a neglected helminth species [107].
In summary, based on the preclinical and clinical studies in animals conducted over the
past 20 years, it can be anticipated that emodepside would be a useful addition to the small
drug armamentarium for human STH infections. As described below, Phase II clinical trials
are planned with emodepside against T. trichiura and hookworm infections. In parallel, confir-
matory preclinical studies should take place with the single product against Strongyloides ster-
coralis in dogs and against Ascaris spp. in pigs, as well as for migrating larvae in the mouse
model.
Current status of development program and outlook
Using a multiple-dose therapeutic scheme, emodepside will be evaluated for its macrofilarici-
dal and long-term sterilizing activity in onchocerciasis patients. Emodepside’s activity against
T. trichiura and hookworms will also be evaluated in parallel.
Although much work remains to be done, current progress suggests that emodepside could
be a valuable future weapon in the arsenal to fight against important NTDs caused by parasitic
nematodes.
Supporting information
S1 Fig. Geographical distribution and status of PC in endemic countries in 2017. PC, pre-
ventive chemotherapy.
(JPG)
S2 Fig. Life cycle of Onchocerca volvulus. Blackflies of the genus Simulium transmit L3 of O.
volvulus onto human skin from where larvae then actively penetrate into the bite wound (1).
In subcutaneous tissues, larvae develop into adult filariae (2). Adults reside in nodules in sub-
cutaneous connective tissues (3) and can live there for up to 15 years. Nodules can contain
multiple relatively shorter male (19–42 mm) and longer female (33–50 cm) worms. Female
worms are viviparous and can produce microfilariae for about 9 years. Microfilariae are
unsheathed and have a length of 220–360 μm and a diameter of 5–9 μm. They can survive up
to 2 years in the human host. Although microfilariae can be found occasionally in peripheral
blood, urine, and sputum, they are typically found in the skin and in the lymphatics of connec-
tive tissues (4). Transmission to the intermediate host occurs when a blackfly ingests microfi-
lariae during blood feeding (5). Microfilariae penetrate the wall of the blackfly’s midgut and
migrate through the hemocoel to the thoracic muscles (6) where the development from first-
stage (7) into L2 and L3 (8) occurs. The iL3 migrate to the blackfly’s proboscis (9) and can
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infect another human when the vector takes a blood meal (1). iL3, third-stage infective larvae;
L2, second-stage larvae; L3, third-stage larvae.
(JPG)
S1 Table. SLO-1 protein database entries included in the phylogenetic analysis. SLO-1,
slowpoke big K+ conductance channel.
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